{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Morabito F"],"pubmed_abstract":["The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no differe"],"journal":["Frontiers in oncology"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9341470"],"repository":["biostudies-literature"],"pubmed_title":["Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials"],"pmcid":["PMC9341470"],"pubmed_authors":["Zamagni E","Palmieri S","Rossi E","Martino E","Musso M","Cavo M","De Stefano V","Frigeri F","Tacchetti P","Mangiacavalli S","Catalano L","Bruzzese A","Bringhen S","Pantani L","Vincelli I","Cascavilla N","Galli M","Gamberi B","Offidani M","Falcone A","Mimmi S","Di Raimondo F","Gentile M","Conticello C","Barone M","Boccadoro M","Morabito F","Musto P","Ria R","Botta C","Tripepi G","Curci P","Vigna E","Pavone V","Mendicino F","Reddiconto G","Neri A","Ballanti S","Mele A","Derudas D","Rocchi S","Rizzello I","Cangialosi C","Garibaldi B","Farina G","Iaccino E","Petrucci M","Mele G"],"additional_accession":[]},"is_claimable":false,"name":"Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials","description":"The present study aimed to develop two survival risk scores (RS) for overall survival (OS, SRSKRd/EloRd) and progression-free survival (PFS, PRSKRd/EloRd) in 919 relapsed/refractory multiple myeloma (RRMM) patients who received carfilzomib, lenalidomide, and dexamethasone (KRd)/elotuzumab, lenalidomide, and dexamethasone (EloRd). The median OS was 35.4 months, with no significant difference between the KRd arm versus the EloRd arm. In the multivariate analysis, advanced ISS (HR = 1.31; P = 0.025), interval diagnosis–therapy (HR = 1.46; P = 0.001), number of previous lines of therapies (HR = 1.96; P < 0.0001), older age (HR = 1.72; P < 0.0001), and prior lenalidomide exposure (HR = 1.30; P = 0.026) remained independently associated with death. The median PFS was 20.3 months, with no differe","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-04T08:08:24.013Z","creation":"2024-11-21T09:50:03.265Z"},"accession":"S-EPMC9341470","cross_references":{}}